Murray Stewart
Director/Miembro de la Junta en X4 PHARMACEUTICALS, INC. .
Fortuna: 193 419 $ al 31/05/2024
Perfil
Murray Willis Stewart is currently a Director at X4 Pharmaceuticals, Inc., a Director at Vivli Center For Global Clinical Research Data, and a Director at VectivBio AG.
Previously, he served as an Independent Director at Amarin Corp.
Plc, an Independent Director at VectivBio Holding AG, the Chief Medical Officer at Rhythm Pharmaceuticals, Inc., the Chief Medical Officer at GSK Plc, and the Executive VP, Head-Research & Development at Novelion Therapeutics, Inc. Dr. Stewart holds a doctorate degree from The University of Southampton.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
X4 PHARMACEUTICALS, INC.
0.11% | 10/06/2024 | 191 504 ( 0.11% ) | 193 419 $ | 31/05/2024 |
Cargos activos de Murray Stewart
| Empresas | Cargo | Inicio |
|---|---|---|
| X4 PHARMACEUTICALS, INC. | Director/Miembro de la Junta | 29/03/2019 |
| Vivli Center For Global Clinical Research Data | Director/Miembro de la Junta | - |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Director/Miembro de la Junta | - |
Antiguos cargos conocidos de Murray Stewart.
| Empresas | Cargo | Fin |
|---|---|---|
| VECTIVBIO HOLDING AG | Director/Miembro de la Junta | 26/06/2023 |
| AMARIN CORPORATION PLC | Director/Miembro de la Junta | 06/03/2023 |
| RHYTHM PHARMACEUTICALS, INC. | Director Técnico/Científico/I+D | 10/09/2021 |
| NOVELION THERAPEUTICS INC. | Director Técnico/Científico/I+D | 17/10/2018 |
| GSK PLC | Director Técnico/Científico/I+D | 01/11/2017 |
Formación de Murray Stewart.
| The University of Southampton | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 4 |
|---|---|
| GSK PLC | Health Technology |
| RHYTHM PHARMACEUTICALS, INC. | Health Technology |
| X4 PHARMACEUTICALS, INC. | Health Technology |
| AMARIN CORPORATION PLC | Health Technology |
| Empresas privadas | 4 |
|---|---|
Novelion Therapeutics, Inc.
 Novelion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelion Therapeutics, Inc. engaged in the development and commercialization of pharmaceuitical products. It focused in providing new standards of care for individuals living with rare diseases. The company was founded on February 3, 1981 and was headquartered in Vancouver, Canada. | Health Technology |
| Vivli Center For Global Clinical Research Data | |
VectivBio Holding AG
 VectivBio Holding AG Pharmaceuticals: MajorHealth Technology VectivBio Holding AG is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of treatments for severe rare conditions with significant unmet medical need. It operates through Switzerland, Canada, and the United States geographical segment. The company was founded by Luca Santarelli on May 22, 2019 and is headquartered in Basel, Switzerland. | Health Technology |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Health Technology |
- Bolsa de valores
- Insiders
- Murray Stewart
